Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | UGCG | Q16739 | 2/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 7/20 | 0.42 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.42 |
| ▸ | CALCA | P06881 | 6/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603721 | 1.00 | CYP3A4 (0.43) | CYP3A4UGCGCALCRLRAMP1CALCA | |
| SCHEMBL6603725 | 1.00 | CYP3A4 (0.43) | CYP3A4UGCGCALCRLRAMP1CALCA | |
| SCHEMBL3958282 | 0.90 | CALCRL (0.43) | CYP3A4CALCRLRAMP1CALCAF10 | |
| SCHEMBL3959260 | 0.81 | CALCRL (0.57) | CYP3A4CALCRLRAMP1CALCA | |
| SCHEMBL3964801 | 0.80 | CALCA (0.67) | CYP3A4CALCRLRAMP1CALCA | |
| SCHEMBL7008363 | 0.80 | SMYD3 (0.43) | F10 | |
| SCHEMBL3962333 | 0.80 | CALCRL (0.55) | CYP3A4CALCRLRAMP1 | |
| SCHEMBL4151549 | 0.80 | CALCRL (0.49) | CYP3A4CALCRLRAMP1CALCA | |
| SCHEMBL4151557 | 0.80 | CALCRL (0.49) | CYP3A4CALCRLRAMP1CALCA | |
| SCHEMBL3963884 | 0.80 | CALCRL (0.54) | CYP3A4CALCRLRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | claimed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | CYP3A4 1258/4885UGCG 4864/4885CALCRL 255/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CYP3A4 759/4885UGCG 4735/4885CALCRL 276/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | CYP3A4 564/4885UGCG 4663/4885CALCRL 364/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CYP3A4 759/4885UGCG 4735/4885CALCRL 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.